Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Jame Abraham from the Cleveland Clinic to discuss key abstracts in the hormone receptor-positive breast cancer space from the San Antonio Breast Cancer Symposium 2024.
Episode Highlights:
• EUROPA Trial: A phase 3 study comparing endocrine therapy versus radiation therapy in early-stage breast cancer patients over 70. Discover how the results may impact clinical practice and patient decision-making.
• TAILORx Study: Updates on the benefits of anthracycline-based chemotherapy for patients with a recurrence score of 31 and above. Learn how this data influences treatment options for younger patients.
• PADMA Study: Insights into the role of CDK4/6 inhibitors combined with endocrine therapy versus chemotherapy in aggressive disease settings. Understand why this combination remains the standard of care.
• EMBER-3 Study: An exploration of the new oral selective estrogen receptor degrader, imlunestrant, and its promising results in combination with abemaciclib for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
Join us as we delve into these important studies and their implications for the future of breast cancer treatment. Don't forget to check out our other conference highlights from ASH 2024 and SABCS 2024!
Subscribe for more insights and updates in oncology!
Website: http://www.oncbrothers.com/
X/Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com
